Table 2:
Safety and efficacy outcomes
| Variable | Value |
|---|---|
| Procedure | |
| Patients (No.) | 21 |
| Patients with technically feasible AVMs (No.) (%) | 19 (90.5%) |
| Procedure-related complications (No.) (%) | 6 (28.6) |
| Transient | 4 (19.0) |
| Permanent, nondisabling | 0 (0) |
| Permanent, disabling | 1 (4.8) |
| Death | 1 (4.8) |
| Non-neurologic | 0 (0) |
| Follow-up | |
| Immediate obliteration after procedure (No.) (%) | |
| In 19 patients with technically feasible AVMs | 16 (84.2) |
| In all 21 patients | 16 (76.2) |
| Imaging follow-up of patients (No.) | 14 |
| Follow-up time (median) (range) | 5.5 (3–15) |
| Obliteration at follow-up (No.) (%) | 13 (92.9) |
| Stable | 1 (7.1) |
| Recanalization | 0 (0) |
| Clinical follow-up of patients within 1 mo (No.) | 21 |
| Events | 6 |
| Stroke | 6 |
| Others | 0 |
| Clinical follow-up of patients beyond 1 mo (No.) | 20 |
| The latest follow-up time (median) (range) | 15 (2–26) |
| Events (No.) | 1 |
| Epilepsy | 1 |
| Others | 0 |
| The latest mRS | |
| 0–2 | 19 |
| 3–5 | 1 |
| 6 | 0 |